Published in Cancer Res on February 01, 2005
Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol (2007) 10.49
Analysis of PALB2/FANCN-associated breast cancer families. Proc Natl Acad Sci U S A (2007) 2.41
A multiplex PCR predictor for aCGH success of FFPE samples. Br J Cancer (2006) 2.33
Genomic imbalances in 5918 malignant epithelial tumors: an explorative meta-analysis of chromosomal CGH data. BMC Cancer (2007) 2.27
Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics. Breast Cancer Res (2010) 1.94
Expression of the embryonic stem cell marker SOX2 in early-stage breast carcinoma. BMC Cancer (2011) 1.74
Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes. Breast Cancer Res (2009) 1.59
Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity. Breast Cancer Res (2007) 1.58
Genomic instability in breast cancer: pathogenesis and clinical implications. Mol Oncol (2010) 1.43
Tumor characteristics as an analytic tool for classifying genetic variants of uncertain clinical significance. Hum Mutat (2008) 1.35
An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients. Ann Oncol (2010) 1.35
Pathology of hereditary breast cancer. Cell Oncol (Dordr) (2011) 1.28
Array-CGH and breast cancer. Breast Cancer Res (2006) 1.26
CpG island hypermethylation of BRCA1 and loss of pRb as co-occurring events in basal/triple-negative breast cancer. Epigenetics (2011) 1.17
The complex genetic landscape of familial breast cancer. Hum Genet (2013) 1.14
A high-throughput pharmaceutical screen identifies compounds with specific toxicity against BRCA2-deficient tumors. Clin Cancer Res (2009) 1.04
Quantitative copy number analysis by Multiplex Ligation-dependent Probe Amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCAness. Breast Cancer Res (2011) 1.03
The changing role of pathology in breast cancer diagnosis and treatment. Pathobiology (2011) 1.02
Expression profiling of familial breast cancers demonstrates higher expression of FGFR2 in BRCA2-associated tumors. Breast Cancer Res Treat (2008) 1.00
Breast tumors from CHEK2 1100delC-mutation carriers: genomic landscape and clinical implications. Breast Cancer Res (2011) 0.95
BRCA1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP53 mutations. BMC Cancer (2010) 0.95
Functional assays for analysis of variants of uncertain significance in BRCA2. Hum Mutat (2013) 0.92
MicroRNAs 206 and 21 cooperate to promote RAS-extracellular signal-regulated kinase signaling by suppressing the translation of RASA1 and SPRED1. Mol Cell Biol (2014) 0.90
Increased level of chromosomal damage after irradiation of lymphocytes from BRCA1 mutation carriers. Br J Cancer (2006) 0.87
Exome sequencing of germline DNA from non-BRCA1/2 familial breast cancer cases selected on the basis of aCGH tumor profiling. PLoS One (2013) 0.86
Drug therapy for hereditary cancers. Hered Cancer Clin Pract (2011) 0.85
Breast cancer genomes--form and function. Curr Opin Genet Dev (2010) 0.85
Phenotypic features and genetic characterization of male breast cancer families: identification of two recurrent BRCA2 mutations in north-east of Italy. BMC Cancer (2006) 0.85
HIF-1α overexpression in ductal carcinoma in situ of the breast in BRCA1 and BRCA2 mutation carriers. PLoS One (2013) 0.84
Copy number imbalances between screen- and symptom-detected breast cancers and impact on disease-free survival. Cancer Prev Res (Phila) (2011) 0.81
SIRAC: Supervised Identification of Regions of Aberration in aCGH datasets. BMC Bioinformatics (2007) 0.80
Genomic profiling of CHEK2*1100delC-mutated breast carcinomas. BMC Cancer (2015) 0.80
MicroRNA-Based Therapeutic Strategies for Targeting Mutant and Wild Type RAS in Cancer. Drug Dev Res (2015) 0.78
Different Array CGH profiles within hereditary breast cancer tumors associated to BRCA1 expression and overall survival. BMC Cancer (2016) 0.77
Bi-allelic alterations in DNA repair genes underpin homologous recombination DNA repair defects in breast cancer. J Pathol (2017) 0.77
Comparative microRNA profiling of sporadic and BRCA1 associated basal-like breast cancers. BMC Cancer (2015) 0.76
Expression of WTH3 in breast cancer tissue and the effects on the biological behavior of breast cancer cells. Exp Ther Med (2015) 0.75
A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med (2002) 58.15
Genome-wide association study identifies novel breast cancer susceptibility loci. Nature (2007) 29.23
Concordance among gene-expression-based predictors for breast cancer. N Engl J Med (2006) 13.50
Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci U S A (2005) 10.85
Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet (2002) 9.71
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature (2012) 8.31
Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet (2013) 8.24
A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet (2007) 7.35
Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet (2009) 7.30
Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet (2008) 6.22
Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res (2005) 5.70
Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat (2008) 5.52
A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet (2010) 4.96
Gene-panel sequencing and the prediction of breast-cancer risk. N Engl J Med (2015) 4.77
Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics (2006) 4.57
Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst (2010) 4.54
Gene expression profiles of primary breast tumors maintained in distant metastases. Proc Natl Acad Sci U S A (2003) 4.47
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling. Cell (2012) 4.01
Mutations in SMAD3 cause a syndromic form of aortic aneurysms and dissections with early-onset osteoarthritis. Nat Genet (2011) 3.93
SDH5, a gene required for flavination of succinate dehydrogenase, is mutated in paraganglioma. Science (2009) 3.72
RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet (2007) 3.63
Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. Proc Natl Acad Sci U S A (2007) 3.58
Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: genotype--phenotype correlations and comparison of diagnostic DNA techniques in Tuberous Sclerosis Complex. Eur J Hum Genet (2005) 3.43
Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet (2008) 3.41
A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Nat Genet (2011) 3.37
Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER). Lancet Oncol (2007) 3.32
BRCA1 tumour suppression occurs via heterochromatin-mediated silencing. Nature (2011) 3.30
The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. Nature (2012) 3.23
Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nat Genet (2012) 3.20
An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. Lancet Oncol (2009) 3.05
An expression profile for diagnosis of lymph node metastases from primary head and neck squamous cell carcinomas. Nat Genet (2005) 3.04
Large genomic deletions and duplications in the BRCA1 gene identified by a novel quantitative method. Cancer Res (2003) 3.02
MicroRNA sequence and expression analysis in breast tumors by deep sequencing. Cancer Res (2011) 3.02
Risk of estrogen receptor-positive and -negative breast cancer and single-nucleotide polymorphism 2q35-rs13387042. J Natl Cancer Inst (2009) 2.88
CHEK2 1100delC mutation is frequent among Russian breast cancer patients. Breast Cancer Res Treat (2006) 2.85
Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat (2011) 2.73
Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. Hum Mol Genet (2011) 2.72
Tumor-associated zinc finger mutations in the CTCF transcription factor selectively alter tts DNA-binding specificity. Cancer Res (2002) 2.52
Modeling precision treatment of breast cancer. Genome Biol (2013) 2.42
SDHAF2 mutations in familial and sporadic paraganglioma and phaeochromocytoma. Lancet Oncol (2010) 2.42
Analysis of PALB2/FANCN-associated breast cancer families. Proc Natl Acad Sci U S A (2007) 2.41
Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet (2013) 2.39
A genome wide linkage search for breast cancer susceptibility genes. Genes Chromosomes Cancer (2006) 2.35
Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation. J Clin Oncol (2006) 2.28
Nonprocessive methylation by Dot1 leads to functional redundancy of histone H3K79 methylation states. Nat Struct Mol Biol (2008) 2.27
Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers. Am J Hum Genet (2013) 2.24
Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clin Cancer Res (2004) 2.17
Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study. Lancet Oncol (2009) 2.17
Chromatin position effects assayed by thousands of reporters integrated in parallel. Cell (2013) 2.16
Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet (2009) 2.13
Identification of a pharmacologically tractable Fra-1/ADORA2B axis promoting breast cancer metastasis. Proc Natl Acad Sci U S A (2013) 2.12
Patterns and mechanisms of ancestral histone protein inheritance in budding yeast. PLoS Biol (2011) 2.11
A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the proliferation, immune response and RNA splicing modules in breast cancer. Breast Cancer Res (2008) 2.09
A protocol for building and evaluating predictors of disease state based on microarray data. Bioinformatics (2005) 2.08
Deep sequencing to reveal new variants in pooled DNA samples. Hum Mutat (2009) 2.04
Insertional mutagenesis identifies multiple networks of cooperating genes driving intestinal tumorigenesis. Nat Genet (2011) 2.02
Potential for bias in studies on efficacy of prophylactic surgery for BRCA1 and BRCA2 mutation. J Natl Cancer Inst (2003) 2.02
Aggressive cardiovascular phenotype of aneurysms-osteoarthritis syndrome caused by pathogenic SMAD3 variants. J Am Coll Cardiol (2012) 1.98
Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. Lancet Oncol (2010) 1.98
Fewer permutations, more accurate P-values. Bioinformatics (2009) 1.91
Cross-validated Cox regression on microarray gene expression data. Stat Med (2006) 1.90
Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res (2010) 1.90
Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk. PLoS Genet (2013) 1.88
The SDH mutation database: an online resource for succinate dehydrogenase sequence variants involved in pheochromocytoma, paraganglioma and mitochondrial complex II deficiency. BMC Med Genet (2005) 1.85
High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer. Cancer Res (2009) 1.82
19p13.1 is a triple-negative-specific breast cancer susceptibility locus. Cancer Res (2012) 1.81
Chromosome 8q23.3 and 11q23.1 variants modify colorectal cancer risk in Lynch syndrome. Gastroenterology (2008) 1.79
Rapid KRAS, EGFR, BRAF and PIK3CA mutation analysis of fine needle aspirates from non-small-cell lung cancer using allele-specific qPCR. PLoS One (2011) 1.78
AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study. Cancer Epidemiol Biomarkers Prev (2007) 1.75
Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol (2005) 1.73
Prediction and assessment of splicing alterations: implications for clinical testing. Hum Mutat (2008) 1.73
Ubiquitin E3 ligase Ring1b/Rnf2 of polycomb repressive complex 1 contributes to stable maintenance of mouse embryonic stem cells. PLoS One (2008) 1.72
Predicting a local recurrence after breast-conserving therapy by gene expression profiling. Breast Cancer Res (2006) 1.69
Common breast cancer susceptibility loci are associated with triple-negative breast cancer. Cancer Res (2011) 1.65
Molecular classification of breast carcinomas by comparative genomic hybridization: a specific somatic genetic profile for BRCA1 tumors. Cancer Res (2002) 1.64
Phenotypic spectrum of the SMAD3-related aneurysms-osteoarthritis syndrome. J Med Genet (2012) 1.62
Inhibition of succinate dehydrogenase dysregulates histone modification in mammalian cells. Mol Cancer (2009) 1.62